Regarding the BRAF V600E mutation in papillary thyroid carcinoma, which statement is MOST accurate?
- A It is present in >90% of follicular variant PTC
- B Its presence mandates radioiodine treatment regardless of staging
- C It is associated with extra-thyroidal extension and lymph node metastasis ✓
- D It confers resistance to surgery but sensitivity to targeted therapy alone
Correct answer: C. It is associated with extra-thyroidal extension and lymph node metastasis
Explanation
BRAF V600E is the most common mutation in classical papillary thyroid carcinoma (~50–60%) and is associated with more aggressive features: extra-thyroidal extension, lymph node metastasis, and RAI-refractory recurrence. It is uncommon in follicular variant PTC which more often harbours RAS mutations. BRAF status alone does not mandate RAI in low-risk disease, but it informs risk stratification and may favour more complete surgical resection.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.